- Report
- November 2025
- 192 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €883EUR$1,000USD£772GBP
€1104EUR$1,250USD£966GBP
- Report
- September 2025
- 250 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- April 2025
- 175 Pages
Global
From €3965EUR$4,490USD£3,468GBP
- Report
- December 2025
- 191 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,246USD£3,169GBP
- Report
- October 2025
- 160 Pages
Global
From €2965EUR$3,358USD£2,593GBP
€3488EUR$3,950USD£3,051GBP
- Report
- October 2025
- 160 Pages
Global
From €2965EUR$3,358USD£2,593GBP
€3488EUR$3,950USD£3,051GBP
- Report
- August 2025
- 180 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €883EUR$1,000USD£772GBP
€1104EUR$1,250USD£966GBP
- Report
- December 2025
- 291 Pages
Global
From €5166EUR$5,850USD£4,519GBP
- Report
- July 2025
- 155 Pages
Global
From €4106EUR$4,650USD£3,592GBP
- Report
- May 2025
- 150 Pages
Global
From €5254EUR$5,950USD£4,596GBP
- Report
- November 2025
- 186 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 197 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 197 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 187 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 199 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 185 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP
- Report
- November 2025
- 182 Pages
Global
From €3131EUR$3,545USD£2,738GBP
€3478EUR$3,939USD£3,043GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more